| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041271532 |
| P356 | DOI | 10.1186/S12933-015-0229-9 |
| P932 | PMC publication ID | 4475300 |
| P698 | PubMed publication ID | 26047614 |
| P5875 | ResearchGate publication ID | 277817431 |
| P50 | author | Yang Xiao | Q59706117 |
| P2093 | author name string | Pengcheng Zhou | |
| Xiaoyan Chen | |||
| Aimin Xu | |||
| Zhiguang Zhou | |||
| Gan Huang | |||
| Weili Tang | |||
| Lingjiao Liu | |||
| Zhaofeng Long | |||
| Yiting Tu | |||
| P2860 | cites work | The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. | Q46445480 |
| Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans | Q46770146 | ||
| Fibroblast growth factor 21 protects against high glucose induced cellular damage and dysfunction of endothelial nitric-oxide synthase in endothelial cells | Q46845830 | ||
| Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study | Q46864783 | ||
| Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. | Q47931952 | ||
| Geometrical risk factors for atherosclerosis in the femoral artery: a longitudinal angiographic study | Q48598432 | ||
| Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. | Q50906635 | ||
| Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. | Q51374403 | ||
| Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. | Q51385454 | ||
| Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques | Q57500042 | ||
| Usefulness of carotid intima-media thickness measurement and peripheral B-mode ultrasound scan in the clinical screening of patients with coronary artery disease | Q73707490 | ||
| Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes | Q82108485 | ||
| FGF-21 as a novel metabolic regulator | Q24523933 | ||
| Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State | Q24625976 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Functional evolutionary history of the mouse Fgf gene family | Q28259938 | ||
| Diagnosis and classification of diabetes mellitus | Q28280909 | ||
| Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile | Q33785827 | ||
| Neck circumference and early stage atherosclerosis: the cardiometabolic risk in Chinese (CRC) study | Q33909387 | ||
| Normal weight diabetic patients versus obese diabetics: relation of overall and abdominal adiposity to vascular health | Q34484460 | ||
| The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. | Q34577053 | ||
| Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease | Q35020888 | ||
| Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients | Q35176887 | ||
| Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. | Q35648897 | ||
| Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease | Q37153759 | ||
| Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue | Q37199307 | ||
| TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway | Q39317227 | ||
| Identification of Predictable Biomarkers in Conjunction to Framingham Risk Score to Predict the Risk for Cardiovascular disease (CVD) in Non Cardiac Subjects | Q40161318 | ||
| Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. | Q41760918 | ||
| Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride | Q42950501 | ||
| Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. | Q42972684 | ||
| Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. | Q43069381 | ||
| Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. | Q43287114 | ||
| Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease | Q43614603 | ||
| Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects | Q46076306 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 72 | |
| P577 | publication date | 2015-06-06 | |
| P1433 | published in | Cardiovascular Diabetology | Q2468083 |
| P1476 | title | Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes | |
| P478 | volume | 14 |
| Q57493364 | A high circulating FGF21 level as a prognostic marker in patients with acute myocardial infarction |
| Q37714724 | Assessed and Emerging Biomarkers in Stroke and Training-Mediated Stroke Recovery: State of the Art. |
| Q38618204 | Contribution of serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death. |
| Q30238666 | Exercise effects on perivascular adipose tissue: endocrine and paracrine determinants of vascular function |
| Q96303466 | Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes |
| Q27686803 | Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders |
| Q39325845 | Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis. |
| Q26766528 | Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk |
| Q58696543 | Fibroblast growth factor 21 inhibits atherosclerosis in apoE-/- mice by ameliorating Fas-mediated apoptosis |
| Q38601292 | Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output |
| Q38635300 | New insights about the putative role of myokines in the context of cardiac rehabilitation and secondary cardiovascular prevention. |
| Q26744232 | Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases |
| Q92431450 | SERUM LEVELS OF FIBROBLAST GROWTH FACTOR 21 IN TYPE 2 DIABETIC PATIENTS |
| Q39197925 | The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension |
| Q39129323 | The Role of Adipocytokines in Coronary Atherosclerosis |
| Q39109051 | The metabolic hormone FGF21 is associated with endothelial dysfunction in hemodialysis patients |
Search more.